The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

Konrad Lewandowski; Magdalena Kaniewska; Katarzyna Karłowicz; Mariusz Rosołowski; Grażyna Rydzewska

doi:10.5114/pg.2021.112681

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

Prz Gastroenterol. 2022;17(1):28-34. doi: 10.5114/pg.2021.112681. Epub 2022 Jan 18.

Authors

Konrad Lewandowski¹, Magdalena Kaniewska¹, Katarzyna Karłowicz¹, Mariusz Rosołowski^{2

3}, Grażyna Rydzewska^{1

4}

Affiliations

¹ Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland.
² Department of Internal Medicine and Hypertension, Medical University of Bialystok, Bialystok, Poland.
³ Department of Hypertension, Gastroenterology and Internal Medicine, Medical University of Bialystok Clinical Hospital, Bialystok, Poland.
⁴ Collegium Medicum, Jan Kochanowski University, Kielce, Poland.

Abstract

Aim: The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinical symptoms and improving quality of life in patients with irritable bowel syndrome (IBS).

Material and methods: In this prospective multicenter clinical trial, we observed a total of 3000 non-hospitalized patients with confirmed IBS who were treated with sodium butyrate in a triglyceride matrix at a dosage of 150 mg twice a day for 12 weeks. The primary outcome was to evaluate the efficacy of sodium butyrate at reducing the severity of clinical symptoms and improving quality of life in patients with IBS.

Results: A total of 2990 complete surveys were collected. A statistically significant improvement in severity of abdominal pain was noticed (p < 0.001). Moreover, flatulence, diarrhea, constipation, urgent pressure for bowel movements, nausea, and vomiting decreased significantly (p < 0.001). Most of the respondents (93.90%) declared that they would continue the therapy and 88.9% would recommend using sodium butyrate to other IBS patients.

Conclusions: Sodium butyrate in the triglyceride matrix, as a postbiotic substance, may be effective in relieving the symptoms of IBS by modifying the intestinal microbiota.

Keywords: irritable bowel syndrome; overweight; sodium butyrate; symptoms.